Genenta Science S.p.A. - American Depositary Shares (GNTA)

Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma Trial

MILAN and NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- In response to evolving market dynamics and strategic opportunities, Genenta Science S.p.A (Nasdaq: GNTA) is embarking on a strategic transformation to evolve into a next-generation strategic industrial consolidator focused on acquiring privately held businesses operating in national-security regulated sectors contemplated by the Italian Golden Power1 legislation. The Company intends to target majority ownership in companies with established operating profitability, typically generating up to approximately €5 million in EBITDA2. In this context, Genenta plans to adopt the new corporate name of Saentra Forge S.p.A. with a new Nasdaq ticker symbol of SAEN3.

MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update regarding the ownership position of its Chief Executive Officer and Co-Founder, Pierluigi Paracchi.

Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its October 27th Registered Direct Offering

Synergy CHC Corp. (NASDAQ: SNYR), a leading consumer health and wellness company, announced continued momentum for its flagship brand FOCUSfactor® following several key milestones and retail expansions across North America, UK, UAE, Turkey and Latin America.

MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with institutional investors to purchase 4,285,715 American Depositary Shares ("ADSs") at an offering price of $3.50 per ADS, for gross proceeds of approximately $15.0 million, before deducting placement agent fees and other estimated offering expenses. All of the securities in the offering were sold by Genenta, and no warrants or other derivative securities were issued in connection with this offering.

Myseum Inc. (NASDAQ: MYSE), a privacy-first social media and technology innovator, is capturing investor and media attention this week as CEO Darin Myman takes to the airwaves, sharing his vision for how Myseum’s technology could dramatically disrupt the social media landscape as we know it. The market has taken notice. MYSE shares have been active this week , closing Wednesday, October 22, 2025, at $2.68 and surging to an intraday high of $3.07 on Thursday on strong volume — reflecting growing investor enthusiasm as the company’s technology gains wider recognition.

MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with a focus on off-the-shelf lentiviral vector (“LVV”) Plasmid DNA technology platform. This new agreement builds and expands on the existing successful partnership between the two companies, which has focused on the production of Plasmid DNA.

Genitourinary Tumor Study Ongoing with Active Screening and Enrollment

Anemocyte established Cell Banks and Plasmids for Viral Vector Production

MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Montalcini Global Biotech Tour” in Doha, Qatar on April 17th, 2025 at the Sheikh Fahad bin Jassim Al Thani theatre, Ministry of Commerce and Industry (MOCI) Building.

MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) to support the expansion of its pipeline by advancing Temferon in metastatic Renal Cell Cancer (mRCC). ETB is a leading private foundation, supervised by the Italian Ministry of Enterprises and Made in Italy, managing over €1,7 billion in assets under management through two funds. With deep expertise in the biomedical sector, ETB is an established authority in identifying and supporting high-potential biotech companies.

Sharing Insights at the 'Italy on the Move' Event and Engaging Investors at Biotech Showcase During JPM Healthcare Week in San Francisco

MILAN and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and in cell-based therapeutics, is pleased to announce that Pierluigi Paracchi, CEO, will attend as a speaker to the Italy-U.S. meeting “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective” scheduled at 2.00 PM on October 25th, 2024 at the U.S. Senate - Washington, D.C. The event is organized by the U.S. National Security Commission on Emerging Biotechnology (NSCEB) and the Italian Embassy in the U.S.

Glioblastoma study achieves milestone with successful dose escalation, setting stage for Phase 2

MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company engaged in the development of a proprietary hematopoietic stem cell therapy for the treatment of a variety of solid tumor cancers. Temferon(TM) is based on ex-vivo gene transfer into autologous Tie2+ hematopoietic stem/progenitor cells (“HSPCs”) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes – TEMs) . Temferon, which is under investigation in a phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is designed to reach solid tumors, induce a durable immune response not restricted to pre-selected tumor antigens nor type, and avoid systemic toxicity, which are some of the main unresolved challenges in immuno-oncology. For more information, visit the company’s website at www.genenta.com .

Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial

MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at several upcoming scientific and investor conferences.

Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication

MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the European Commission has granted Orphan Drug Designation (ODD) to Temferon™ for the treatment of glioma. Glioblastoma Multiforme (GBM) is the first clinical indication of Temferon.

Prof. Luigi Naldini will present updates on the efficacy of Temferon in pre-clinical solid tumor models and preliminary clinical biological data confirming in patients

MILAN, Italy and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced its fiscal year 2022 financial results and that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 (the “Annual Report”) with the Securities and Exchange Commission ("SEC"). The Annual Report can be accessed on the Company's investor relations website at https://ir.genenta.com/financial-information/sec-filings as well as the SEC's website at http://www.sec.gov.

Genenta (NASDAQ: GNTA) is a clinical-stage biotechnology company engaged in the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon(TM) is based on ex-vivo gene transfer into autologous Tie2+ hematopoietic stem/progenitor cells (“HSPCs”) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes – TEMs). Temferon(TM), which is under investigation in a phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is designed to reach solid tumors, induce a durable immune response not restricted to pre-selected tumor antigens nor type, and avoid systemic toxicity, which are some of the main unresolved challenges in immuno-oncology. For more information, visit the company’s website at www.genenta.com .

Genenta Sciences (NASDAQ: GNTA) is a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. Their platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor micro-environment. Genenta’s lead product candidate, Temferon, precisely targets the delivery of interferon-alpha to the tumor micro-environment, minimizing systemic toxicity while breaking tumor-induced immune tolerance. Their treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics. For more information, visit the company’s website at www.genenta.com .